GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (FRA:ATQP) » Definitions » Interest Expense

Vericel (FRA:ATQP) Interest Expense : €-0.6 Mil (TTM As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Vericel Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Vericel's interest expense for the three months ended in Dec. 2024 was € -0.1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.6 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Vericel's Operating Income for the three months ended in Dec. 2024 was € 17.6 Mil. Vericel's Interest Expense for the three months ended in Dec. 2024 was € -0.1 Mil. Vericel's Interest Coverage for the quarter that ended in Dec. 2024 was 120.05. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Vericel Interest Expense Historical Data

The historical data trend for Vericel's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Interest Expense Chart

Vericel Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 - -0.35 -0.55 -0.59

Vericel Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.14 -0.14 -0.14 -0.15

Vericel Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vericel  (FRA:ATQP) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vericel's Interest Expense for the three months ended in Dec. 2024 was €-0.1 Mil. Its Operating Income for the three months ended in Dec. 2024 was €17.6 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was €85.6 Mil.

Vericel's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Interest Coverage=-1* Operating Income (Q: Dec. 2024 )/Interest Expense (Q: Dec. 2024 )
=-1*17.647/-0.147
=120.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Vericel Business Description

Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Vericel Headlines

No Headlines